Niagen Bioscience, Inc. current report, 08 April 2019

SEC Filing Summary: ChromaDex Corporation (8-K)

Business Context and Reporting Period

This Form 8-K was filed by ChromaDex Corporation on April 8, 2019. The registrant is incorporated in Delaware and maintains its principal executive offices in Los Angeles, California. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate communication rather than a financial statement.

Material Changes

No material financial changes or operational updates are detailed in the body of this filing. The report solely documents the release of a presentation regarding investor frequently asked questions.

Guidance, Outlook, and Management Commentary

  • Regulation FD Disclosure: On April 8, 2019, the company released a presentation addressing investor frequently asked questions.
  • Availability: The presentation is available on the company's website and is attached to this filing as Exhibit 99.1.
  • Legal Status: The information furnished in this Item 7.01 and the attached exhibit is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liability of that section, nor is it incorporated by reference into other filings unless expressly stated.

Key Facts for Investor Verification

  • Verify the content of the "Investor Frequently Asked Questions" presentation attached as Exhibit 99.1 for specific business updates.
  • Confirm the company's status as an emerging growth company (indicated as checked in the filing).
  • Note that the filing was signed by Kevin M. Farr, Chief Financial Officer.